A Phase I Study of Intravenous CCI-779 in Combination With Bryostatin-1 in Solid Tumors (10038414).
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2014
At a glance
- Drugs Bryostatin-1 (Primary) ; Temsirolimus (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 19 Feb 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov, last updated 19-Feb-2009.
- 19 Feb 2009 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.